For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
Keros Therapeutics Inc (NASDAQ: KROS) closed the day trading at $9.55 down -6.28% from the previous closing price of $10.19. In other words, the price has decreased by -$6.28 from its previous closing price. On the day, 1.16 million shares were traded. KROS stock price reached its highest trading level at $10.1 during the session, while it also had its lowest trading level at $9.41.
Ratios:
For a better understanding of KROS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 21.45 and its Current Ratio is at 21.45. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.
On January 17, 2025, Wedbush Downgraded its rating to Neutral which previously was Outperform but kept the price unchanged to $15.
Oppenheimer reiterated its Outperform rating for the stock on December 16, 2024, while the target price for the stock was revised from $102 to $63.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 13 ’24 when GORDON CARL L sold 250,000 shares for $44.01 per share. The transaction valued at 11,002,500 led to the insider holds 119,522 shares of the business.
ORBIMED ADVISORS LLC sold 250,000 shares of KROS for $11,002,500 on Aug 13 ’24. The Director now owns 119,522 shares after completing the transaction at $44.01 per share. On Aug 13 ’24, another insider, OrbiMed Genesis Master Fund, L, who serves as the Shareholder of the company, bought 29,400 shares for $44.84 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KROS now has a Market Capitalization of 387367104 and an Enterprise Value of -153702448. For the stock, the TTM Price-to-Sale (P/S) ratio is 109.12 while its Price-to-Book (P/B) ratio in mrq is 0.68. Its current Enterprise Value per Revenue stands at -43.296 whereas that against EBITDA is 0.733.
Stock Price History:
The Beta on a monthly basis for KROS is 1.39, which has changed by -0.8507346 over the last 52 weeks, in comparison to a change of 0.08089435 over the same period for the S&P500. Over the past 52 weeks, KROS has reached a high of $72.37, while it has fallen to a 52-week low of $9.71. The 50-Day Moving Average of the stock is -14.14%, while the 200-Day Moving Average is calculated to be -75.20%.
Shares Statistics:
Over the past 3-months, KROS traded about 1.32M shares per day on average, while over the past 10 days, KROS traded about 724350 shares per day. A total of 40.55M shares are outstanding, with a floating share count of 32.88M. Insiders hold about 18.93% of the company’s shares, while institutions hold 77.92% stake in the company. Shares short for KROS as of 1741910400 were 4019396 with a Short Ratio of 3.05, compared to 1739491200 on 4132154. Therefore, it implies a Short% of Shares Outstanding of 4019396 and a Short% of Float of 13.489999999999998.
